Valneva SE (VALN) EBITDA (2021 - 2026)
Valneva SE (VALN) posted EBITDA of -$21.3 million for Q1 2026, up 15.65% sequentially from -$25.3 million in Q4 2025, and down 3276.1% YoY from $670873.2 in Q1 2025.
Analysis
Valneva SE (VALN) EBITDA (2021 - 2026) Analysis & Trends
Valneva SE has reported EBITDA for 6 years, with the latest figure at -$21.3 million in Q1 2026.
- Quarterly EBITDA fell 3276.1% year-over-year to -$21.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$89.7 million (down 104.67% YoY) and the FY2025 annual result came in at -$69.1 million, down 294.18% from the prior year.
- EBITDA rose to -$21.3 million in Q1 2026 per VALN's latest filing, from -$25.3 million in the prior quarter.
- Over five years, EBITDA peaked at $38.7 billion in Q4 2022 and troughed at -$38.1 billion in Q3 2022.
- A 5-year average of $14.7 million and a median of -$18.1 million in 2024 frame the typical range for EBITDA.
- The widest YoY moves for EBITDA: up 19080.79% in 2022, down 21259.55% in 2022.
- Over 5 years, EBITDA stood at $38.7 billion in 2022, then slumped by 100.05% to -$20.7 million in 2023, then increased by 18.79% to -$16.8 million in 2024, then slumped by 50.56% to -$25.3 million in 2025, then increased by 15.65% to -$21.3 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$21.3 million, -$25.3 million, and -$37.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.72 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 63.56 Bn | 58.38 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.87 Bn | 52.73 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.08 Bn | 34.98 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.20 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.54 Bn | 27.70 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Valneva SE | 584.00 Mn | 442.75 Mn | 1.86 Mn | -25.46 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25.46 Mn |
| Mar 31, 2026 | -21.31 Mn |
| Dec 31, 2025 | -25.26 Mn |
| Sep 30, 2025 | -37.06 Mn |
| Jun 30, 2025 | -6.11 Mn |
| Mar 31, 2025 | -631,130.66 |
| Dec 31, 2024 | -16.78 Mn |
| Sep 30, 2024 | -8.30 Mn |
| Jun 30, 2024 | -18.14 Mn |
| Mar 31, 2024 | 79.30 Mn |
| Dec 31, 2023 | -20.66 Mn |
| Sep 30, 2023 | -19.27 Mn |
| Jun 30, 2023 | -17.42 Mn |
| Mar 31, 2023 | -13.20 Mn |
| Dec 31, 2022 | 38.67 Bn |
| Sep 30, 2022 | -38.14 Bn |
| Jun 30, 2022 | -130.93 Mn |
| Mar 31, 2022 | -14.93 Mn |
| Dec 31, 2021 | 201.58 Mn |
| Sep 30, 2021 | -178.58 Mn |